Prevention and monitoring of hepatotoxicity among patients receiving antituberculosis medications

Fei Yuan Hsiao, Yu Hsuan Yen, Chun-Nin Lee, Weng Foung Huang, Hsiang Yin Chen

研究成果: 雜誌貢獻文章同行評審

1 引文 斯高帕斯(Scopus)


Antituberculosis therapy frequently causes hepatotoxicity. The study is to evaluate the appropriateness of liver function monitoring during antituberculosis therapy. Two hundred forty five patients treated with antituberculosis agents were included. Abnormal baseline liver function (LFT) was the most significant risk factor for developing hepatotoxicity during the therapy (adjusted OR 23.48; 95%CI: 9.74-56.61). However, the baseline aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were only checked in 76.2% and 75.4% subjects in the hepatotoxic group; and even lower to 58.5% and 57.8% for the non-hepatotoxic group. Although smoking, severe drinking, age, gender and concurrent diseases were significant risk factors, the logistic regression showed that only abnormal baseline LFT (adjusted OR 2.21; 95%CI: 1.22-4.02) and age (adjusted OR 1.02; 95%CI: 1.01-1.04) were determinants of patients receiving follow-up liver function tests (LFTs). Effective strategies to improve the monitoring of liver function should be established to ensure patient safety.
頁(從 - 到)107-114
期刊Taiwan Pharmaceutical Journal
出版狀態已發佈 - 12月 2009

ASJC Scopus subject areas

  • 藥學科學
  • 藥理


深入研究「Prevention and monitoring of hepatotoxicity among patients receiving antituberculosis medications」主題。共同形成了獨特的指紋。